Background: Treatment for adult Philadelphia chromosome+ acute lymphoblastic leukemia includes using dasatinib, a tyrosine kinase inhibitor. Cutaneous
Introduction
Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells with unknown pathogenicity diagnosed in between 3,000 to 4,000 people in the U.S each year, two-thirds of them are children. [1] [2] In adult ALL, the most frequent chromosomal translocation is t(9;22), known as the Philadelphia chromosome, which binds breakpoint cluster (BCR) signalling proteins to ABL tyrosine kinases (TKs) resulting in uncontrollable ABL tyrosine kinase (TK) activity. [1] [2] [3] In the past two decades, tyrosine kinase inhibitors (TKIs) that specifically inhibit certain TKs, such as those involved in ALL's pathogenesis, have successfully treated ALL. [4] [5] Dasatinib, an orally available second-generation ABL kinase inhibitor, is approved to treat adults with Philadelphia chromosome positive (Ph+) ALL who developed resistance to or intolerance of other ABL TKIs such as imatinib (Gleevec®). [3] [4] [5] [6] Multiple factors such as exposure to ionizing radiation, chemical agents, UV radiation, human papilloma virus, and immunosuppression can predispose patients to develop different types of cutaneous squamous cell carcinomas (SCCs). [5] [6] [7] Keratoacanthomas (KAs) are currently classified as one type of cutaneous squamous cell carcinoma (SCC), but this concept is controversial as another opinion is that it is a distinct self-resolving squamoproliferative lesion that may regress due to upregulation of the cell death/apoptosis pathway. 8 Clinically, KAs may be a single or multiple rapidly developing crateriform lesions in a few weeks or months and may spontaneously resolve in 6 months without any treatment (Figure 1) • Keratoacanthomas are initially rapid growing neoplasms (10 days -2 months) that stabilize and often regress without surgical removal unlike other types of cutaneous squamous cell carcinomas.
• Treating adult Philadelphia chromosome+ acute lymphoblastic leukemia with dasatinib and other tyrosine kinase inhibitors may cause rapid onset of keratoacanthoma type squamous cell carcinomas.
other types of cutaneous SCCs such as those arising from the much more common actinic keratosis and in situ squamous cell carcinomas. A clinical history of rapid onset of such lesions within a few months is a valuable clue to their diagnosis and establishing their prognosis. Herein we report a case of a patient who developed multiple KAs within two months after starting treatment with dasatinib for Ph+ ALL. Sometimes KAs arise due to hyperactive epidermal growth factor receptor tyrosine kinases that subsequently activate the RAS and MAPK signalling pathways. [5] [6] [7] [8] [9] However, the incidence and treatment of KA type SCCs induced by TKIs are not well defined, but investigations to clarify if KAs are SCCs and distinct from a molecular perspective are on-going. [6] [7] [8] A signed copy of consent to publish this manuscript was obtained from the patient.
The Case
A 77-year-old Caucasian male presented to the dermatology clinic for sudden onset of nodular skin lesions found on the arms, legs, back, and chest. The patient showed no significant evidence of severe sun exposure or any ionizing radiation that would predispose him to develop these lesions. He had a medical history of a malignant melanoma on the left side of his upper back treated 9 years prior to his dermatology clinic visit. He had no family history of ALL, but his mother had treatment for a basal cell carcinoma. The diagnosis of Ph+ ALL was confirmed two months prior to his initial dermatology clinic visit and his skin lesions were first noticed weeks after starting treatment for Ph+ ALL. His oncologist started treatment with oral 400 mg tablet of antiviral drug Acyclovir taken twice daily, oral multi BCR/ABL TKI dasatinib (Sprycel®) 140 mg tablet taken once daily, and oral ondansetron (Zofran®) 8 mg tablet to be taken as needed. Within two months after starting this treatment, the patient achieved molecular remission of Ph+ ALL with undetectable BCR-ABL. The patient maintained the treatment regimen throughout his oncology clinic visits. While on this treatment regimen that included dasatinib, the patient developed mild anemia (RBC 3.50 M/uL). However, the patient did not have any fevers, chills, night sweats, nausea, vomiting, abdominal pain, chest pain, shortness of breath, or skin rash. The patient's oncologist confirmed his adherence to medication with regularly scheduled visits. The patient's wife also confirmed compliance with treatment regimen, and the patient was overall happy with the treatment results.
The patient's skin lesions were nodular, erythematous, hyperkeratotic, and first observed two weeks after starting treatment with dasatinib (Figure 1) . The initial shave biopsy in the dermatology clinic was a 13 x 13 x 6mm tan nodule on the left volar forearm (Figure 1 ) to identify if it was a KA type of SCC, dermatitis medicamentosa, leukemia cutis, basal cell carcinoma or, less likely, a recurrent malignant melanoma. The dermatopathologist confirmed this nodule was a KA variant of SCC with clear margins (Figure 2) . On the patient's next dermatology clinic visit one week following the initial skin biopsy, a repeat skin biopsy on the left superior forearm confirmed the second lesion was also a KA variant of SCC. These two KAs with typical biopsy features and clinical multiple other KAs (23 in total), their rapid clinical onset, and previous reports of KAs in patients treated with other TKIs (sorafenib, nilotinib) are consistent with the patient developing KAs induced by dasatinib used to treat Ph+ ALL.
On follow-up visit three weeks after the preceding biopsy, no new lesions were detected and existing lesions showed hyperkeratotic regression typical of KAs. Due to a risk of slow healing and excessive bleeding, a referral to a Mohs surgeon was made to excise the 20 remaining KAs below the patient's waist. The three remaining KAs above the waist were excised in the dermatology clinic with sufficient time between visits to prevent slow healing and/or bleeding complications. The oncologist recommended that the patient continue 140 mg dasatinib and stop taking Acyclovir. An initial management challenge was to determine which physician should be managing his skin lesions -his oncologist, the dermatologist, or the Mohs surgeon? After initially cancelling his dermatology clinic appointment, convenient appointment times were made for the patient to see the oncologist and the dermatologist. Both clinicians and the patient are satisfied with the outcome of treatment and he continues close monitoring to detect new lesions or other adverse events. The patient was eager to achieve resolution of his skin lesions so he was compliant with all treatments, diagnostic tests, and has continued dasatinib for treatment of his Ph+ ALL.
Discussion
Keratoacanthomas (KAs) are commonly thought to be a low-grade skin cancer or a distinct self-resolving squamoproliferative lesion that is very similar phenotypically to squamous cell carcinoma (SCC) and originates in the skin's pilosebaceous glands or hair follicles. 10 KAs typically and rapidly grow a few weeks to a few months, as a crateriform lesion with hyperkeratotic regression. 10 The patient's rapidly growing lesions were scattered throughout his chest, back, and extremities with no correlation between their location and intense sun exposure sites starting two months after treatment for Ph+ acute lymphoblastic leukemia (ALL) by his oncologist who referred the patient to the dermatology clinic. A shave biopsy was determined to be the ideal diagnostic approach. While multiple shave biopsies are diagnostically useful, only one or two biopsies were performed per visit to insure that the patient would not bleed excessively. Legend: SCC, KA types are characterized "by an incomplete or asymmetric crateriform pattern with bulging borders and irregular nests of squamous cells invading the dermis". 10 Hematoxylin and Eosin (H&E) stain used on biopsy specimen at 10x magnification.
The Mohs technique was determined to be the most appropriate for lesions below the patient's waist due to its accuracy and minimally invasive approach.
To define the etiology of the sudden and aggressive appearing KAs, the focus changed to a family history of skin cancers, a comorbid neoplasm related to Ph+ ALL, or possible adverse reaction to one of his medications including the tyrosine kinase inhibitor, dasatinib, which has an extensive list of cutaneous side effects including rashes, redness, peeling, but currently there is no reference of cutaneous SCC, KA type (Sprycel. Available from: http://www.sprycel.com/side-effects, updated 2015 August 15; cited 2015 August 16).
The current TKI literature implies a relationship between eruptive epitheliomas such as KAs and the TKIs sorafenib and nilotinib. 5, [10] [11] There are multiple mutations associated with Ph+ ALL and interest is focused on the signaling pathways are targeted in the pathogenesis of KA type of SCC by dasatinib and other TKIs. 12 One study documented a patient developing multiple cutaneous SCCs (KAs) shortly after starting treatment with nilotinib for chronic myeloid leukemia (CML). 5 Multiple patients treated for solid tumors with sorafenib also developed multiple KA type lesions within few weeks to months after starting treatment. [10] [11] Our in-depth literature review did not find any documented cases of a Ph+ ALL with a patient with KA type eruptive Thukral S, et al.
Multiple Keratoacanthomas, Philadelphia Chromosome+ Acute Lymphoblastic Leukemia, and Dasatinib: A Case Report epitheliomas or SCCs after starting therapies using dasatinib. Treatment options for patients treated with TKIs included a CML patient who developed KA type SCC lesions after starting treatment with nilotinib and the number of new lesions decreased after retinoid treatment and all existing SCCs were surgically excised. 5 The induction of KAs may be TKI specific as patients with KAs treated with sorafenib for solid tumors had regression of existing KA, SCC type after switching to a different TKI (sunitinib) or discontinuing sorafenib. [10] [11] The mechanisms involved in causing the SCC, KA type lesions in our patient are not yet documented. Since no prior report was found to document eruptive epitheliomas, KAs, or SCC types were induced by dasatinib in the treatment of Ph+ ALL, we presume that this case is the first of its kind.
Conclusion
The treatment of Ph+ ALL with dasatinib has been associated with numerous different systemic and skin adverse events; however, its association with the rapid onset of keratoacanthoma type, squamous cell carcinomas in this rare form of ALL is not previously documented. With increased usage of dasatinib to treat adult Ph+ ALL, it is important to recognize its association with the possible rapid development of eruptive epitheliomas, keratoacanthoma type.
